evinacumab-dgnb (Evkeeza)

Indications

• homozygous familial hypercholesterolemia

Dosage

8 mL 2.3 mL of 150 mg/mL

Adverse effects

• common 10%
  • nasopharyngitis
• less common (1-10%)
  • flu-like symptoms (7%)
  • infusion-related reactions (7%)
  • dizziness (6%)
  • rhinorrhea (5%)
  • nausea (5%)
  • extremity pain (4%)
  • asthenia (4%)
  • constipation (<3%)
  • upper respiratory tract infection (<3%)
  • nasal congestion (<3%)
  • abdominal pain (<3%)
• other
  • transient, mild-to-moderate decreased diastolic blood pressure
  • increased heart rate
• serious
  • anaphylaxis (1%)

• drug adverse effects of anti-hyperlipidemic agents
• drug adverse effects of pharmaceutical monoclonal antibodies

Mechanism of action

• recombinant human monoclonal Ab
  • binds to & inhibits angiopoietin-like 3 (ANGPTL3) leading to decreased LDL-C, HDL-C, & triglycerides
  • inhibition of ANGPTL3 induces accelerated hydrolysis of VLDL particles
  • up-regulation of apolipoprotein-B containing lipoprotein clearance

More general terms

• anti-hyperlipidemic agent
• pharmaceutical monoclonal antibody